Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Deferred Tax Assets (2016)

Enanta Pharmaceuticals (ENTA) has disclosed Current Deferred Tax Assets for 3 consecutive years, with $1.1 million as the latest value for Q2 2016.

  • For the quarter ending Q2 2016, Current Deferred Tax Assets fell 34.72% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Jun 2016, down 34.72%, and an annual FY2015 reading of $1.4 million, down 86.99% over the prior year.
  • Current Deferred Tax Assets was $1.1 million for Q2 2016 at Enanta Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Current Deferred Tax Assets topped out at $11.2 million in Q2 2014 and bottomed at $1.1 million in Q2 2016.
  • Average Current Deferred Tax Assets over 3 years is $3.6 million, with a median of $1.6 million recorded in 2015.
  • Peak annual rise in Current Deferred Tax Assets hit 17.28% in 2015, while the deepest fall reached 86.99% in 2015.
  • Year by year, Current Deferred Tax Assets stood at $1.3 million in 2014, then rose by 17.28% to $1.6 million in 2015, then fell by 27.45% to $1.1 million in 2016.
  • Business Quant data shows Current Deferred Tax Assets for ENTA at $1.1 million in Q2 2016, $1.6 million in Q1 2016, and $1.6 million in Q4 2015.